/
/
Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit
This content is Free Access.
1Protein Crystallization Lab,Emerald Bio, 2Molecular Biology Lab,Emerald Bio, 3Scientific Sales Representative,Emerald Bio, 4Group Leader II,Emerald Bio, 5Group Leader I,Emerald Bio, 6Chair of Advisory Board,Emerald Bio, 7Director of Multi-Target Services,Emerald Bio, 8Senior Project Leader,Emerald Bio, 9Project Leader II & SSGCID Site Manager,Emerald Bio
Capítulos
- 00:05Título
- 02:20Construct Design
- 04:07Polymerase Incomplete Primer Extension (PIPE) Cloning
- 06:14Expression Optimization
- 08:21Large Scale Fermentation
- 09:40Protein Purification – Cell Lysis
- 10:54Protein Purification – Affinity Chromatography
- 13:04Protein Purification – Affinity Tag Cleavage
- 14:47Protein Purification – Size-exclusion Chromatography (SEC)
- 15:42Protein Crystallization
- 17:03Crystal Harvesting
- 18:15Crystal Screening/Data Collection
- 19:27Results: 3D Structure Determination of Influenza Virus PB2
- 21:05Conclusion
Structure-based drug design plays an important role in drug development. Pursuing multiple targets in parallel greatly increases the chance of success for lead discovery. The following article highlights how the Seattle Structural Genomics Center for Infectious Disease utilizes a multi-target approach for gene-to-structure determination of the PB2 influenza A subunit.
Tags
Multi-targetParallel ProcessingGene-to-structure DeterminationInfluenza Polymerase PB2 SubunitPandemic OutbreaksInfluenza Virus InfectionPoint MutationsVirulence FactorAntiviral Drug TargetStructural Genomics ProgramNational Institute Of Allergy And Infectious Disease (NIAID)Emerald BioSeattle Structural Genomics Center For Infectious Disease (SSGCID)Three-dimensional Protein StructuresNIAID Category A-C PathogensStructure-based Drug DesignDrug Development
